In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Jenny HögströmCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5932-0146 Hanna M DohCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0781-611X Aidan KumpCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0009-0002-6491-578X Boryana PetrovaDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9996-9353 Peng WangDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8118-4929 Jonathan D LeeCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1229-0098 Kaisa KoivulaCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0009-0007-9055-3897 Nina KozlovaCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4944-7917 Kayla A CruzCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8880-5804 Su Min HongCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0009-0006-8472-9924 Camila PereaCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0009-0002-1159-4863 Arjun GargDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0009-0003-1676-630X Michal WeitmanDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8061-3840 Conor L EvansWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2185-6505 Jonathan L ColoffDepartment of Physiology and Biophysics, University of Illinois Cancer Center, University of Illinois College of Medicine, Chicago, IL, USA.ORCID 0000-0003-4726-3097 Jaymin M PatelCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Gerburg M WulfCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7868-6231 Laura C CollinsDepartment of Pathology, and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Naama KanarekDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2068-3908 Taru MuranenCancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4158-9002 Funding
Using patient-derived co-culture models of breast cancer to develop new treatment strategies targeting succinate signaling.R21CA292302 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MURANEN, TARU ELIISA · 2024 to 2024
$445kDeciphering the Transcriptomic Basis of Chemo FogK99CA293268 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Jonathan D Lee · 2025 to 2026
$271kNCI NIH HHS K99 CA293268NCI NIH HHS R21 CA292302
6 · The paper itselfAbstract
Resistance to standard-of-care therapies remains a major clinical challenge in the treatment of the most common breast cancer, the hormone receptor-positive (HR+) subtype. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in early-stage HR+ disease, yet many patients relapse. Resistance mechanisms of relapsed tumors include genetic alterations, but in many cases, no genetic drivers are identified. Here, we investigated mechanisms underlying resistance to CDK4/6 inhibitors using breast cancer patient-derived models and tumors. We identified an unexpected, noncanonical nuclear function of fumarylacetoacetate hydrolase (FAH), an enzyme in the tyrosine catabolism pathway, as a driver of resistance. FAH translocated to the nucleus upon CDK4/6 inhibition, where it interacted with cyclin-dependent kinase 9 (CDK9), and promoted resistance. Nuclear FAH was enriched in tumors from relapsed patients, and inhibition of CDK9 reversed FAH-mediated resistance. These findings establish nuclear FAH as a biomarker of resistance and revealed CDK9 as a therapeutic vulnerability in CDK4/6 inhibitor-resistant HR+ breast cancer.
Indexed as
Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmHydrolasesProtein Kinase InhibitorsAnimalsCell Line, TumorCyclin-Dependent Kinase 9FemaleHumansMiceTyrosineCDK4 protein, humanCDK6 protein, humanCDK9 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 9HydrolasesProtein Kinase InhibitorsTyrosine
Identifiers
PMID42814811
PMCPMC13626039
What OpenQuestion holds
Textmetadata
Read underepoch 390